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GIOVERVIEWSECTION I: FGIDs: BACKGROUND INFORMATIONFunctional Gastrointestinal Disorders: History, Pathophysiology,
Clinical Features, and Rome IV
Douglas A. Drossman
Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology; Center of Functional GI and Motility
Disorders, University of North Carolina; and Rome Foundation, Chapel Hill, North CarolinaFunctional gastrointestinal disorders (FGIDs), the most
common diagnoses in gastroenterology, are recognized by
morphologic and physiological abnormalities that often
occur in combination including motility disturbance,
visceral hypersensitivity, altered mucosal and immune
function, altered gut microbiota, and altered central ner-
vous system processing. Research on these gut–brain
interaction disorders is based on using specific diagnostic
criteria. The Rome Foundation has played a pivotal role in
creating diagnostic criteria, thus operationalizing the
dissemination of new knowledge in the field of FGIDs.
Rome IV is a compendium of the knowledge accumulated
since Rome III was published 10 years ago. It improves
upon Rome III by: (1) updating the basic and clinical
literature; (2) offering new information on gut microenvi-
ronment, gut–brain interactions, pharmacogenomics, bio-
psychosocial, gender and cross-cultural understandings of
FGIDs; (3) reduces the use of imprecise and occasionally
stigmatizing terms when possible; (4) uses updated diag-
nostic algorithms; and (5) incorporates information on the
patient illness experience, and physiological subgroups or
biomarkers that might lead to more targeted treatment.
This introductory article sets the stage for the remaining
17 articles that follow and offers a historical overview of
the FGID field, differentiates FGIDs from motility and
structural disorders, discusses the changes from Rome III,
reviews the Rome committee process, provides a bio-
psychosocial pathophysiological conceptualization of
FGIDs, and offers an approach to patient care.
Keywords: Functional GI Disorders; Rome Foundation; Rome
Criteria; History; Biopsychosocial Model; Neuro-
gastroenterology; Patient Provider Relationship; Rome IV;
Classification; Diagnosis; Treatment Approach.
lthough descriptions of functional gastrointestinalAbbreviations used in this paper: CNS, central nervous system; FGID,
functional gastrointestinal disorder; GI, gastrointestinal; IBS, irritable
bowel syndrome; SOD, sphincter of Oddi.
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http://dx.doi.org/10.1053/j.gastro.2016.02.032Asymptoms have been noted for centuries, the func-
tional gastrointestinal disorders (FGIDs) emerged only over
the past several decades. Our conceptual understanding of
their origins and clinical features evolved from a dualistic
and reductive perspective to a more comprehensive bio-
psychosocial model,1,2 and the scientific bases for symptom
generation changed from being disorders of motility to the
more inclusive disturbances of neurogastroenterology and
brain–gut interactions.3 This evolution has legitimized
FGIDs to patients and health care providers and nurtured
the science to better characterize these disorders and pro-
duce new drug discoveries and treatments.The Rome Foundation has its origins in the late 1980s, at a
time when there was little understanding of the pathophysi-
ology of FGIDs, no established classification system, and no
guidelines for standardized research of the patients. Subse-
quently, the Foundation has played a pivotal role in oper-
ationalizing the research and disseminating the knowledge
surrounding these disorders. Also, by gathering experts from
around the world who use more positive parameters for
diagnosis and perform fewer studies to exclude other disease,
the Rome Foundation identifies experts who are in the best
position to provide guidelines for diagnosis and treatment.
History of the Functional
Gastrointestinal Symptoms and
Disorders and the Role
of Psychosocial Factors
Throughout recorded history, the bowels and intestinal
activity have had meanings that go beyond their actual
function. They usually are considered private and shrouded
in mystery. Their dysfunction is linked to embarrassment,
emotion, and shame, and proper bowel functioning is
thought to be required for general well-being. We also
recognize bowel function and dysfunction as being related
closely to stress and emotion: “I find this hard to swallow,”
“I cannot stomach that any longer,” and “I feel butterflies in
my stomach.” Conversely, and likely as evolving for health
benefit, intestinal contents and feces are noxious to the
senses; the sight, smell, and touch of these can lead to
avoidant emotional responses, nausea, and vomiting. Thus,
brain and gut more than any other organ systems are
hardwired; each has a nervous system that is linked and
derived from the same anlage, the embryonic neural crest.
This brain–gut connection also explains why stress and
psychological factors are linked so closely to gut function and
dysfunction, gastrointestinal symptoms, illness, and disease.
Understanding how these factors relate to one another has
evolved from the changing mores, belief systems, or
explanatory (folk) models of the time. Explanatory models of










EWillness and disease arise and change in response to new
technologies and the need for clinical solutions; however,
new models require acceptance by society based on theories
that may have existed for centuries and across cultures.
Thus, the perception of symptoms may be considered
problems in one population, but ignored in another. This
perception can occur simply based on prevalence, in that
symptoms that are more common would be considered
normal. For example, among lower socioeconomic Mexican
Americans in the Southwest, diarrhea is common and is not
usually perceived as an illness requiring health care seeking,4
whereas in other sectors of society, diarrhea is considered an
illness to be investigated or treated.
Another important influencing factor for a symptom to
be perceived as an illness relates to its congruence with
dominant or major value orientations: that is, how it is
recognized by the society. In some nonliterate societies, the
description of hallucinations is accepted with interest,
possibly indicating specialness, having magical powers, or
connecting with spiritual beings. However, in Western so-
ciety, the admission of a hallucination would be considered
a potentially serious medical problem possibly caused by
psychosis or drug toxicity.5 Societal and cultural values also
can affect even the development or nondevelopment of
symptoms. Margaret Mead noted that nausea, which is a
common and acceptable part of pregnancy in the West, does
not occur among the Arapesh of New Guinea, because there
is denial that a child exists until shortly before birth.6 The
following section traces cultural influences on research and
knowledge of gastrointestinal symptoms and illness,
consequently leading to the identification and categorization
of functional gastrointestinal (GI) disorders.Antiquity Through the Late 19th Century:
Holism and Cartesian Dualism
The possibility that passions or emotions could lead to
the development of medical disease was first proposed by
the Greek physician Claudius Galen and has been upheld by
medical writers into the 21st century. This supposition is
not surprising because we observe the effects of intense
emotion on autonomic arousal, leading to diarrhea, the
production of chest or abdominal pain, or even sudden
death.7 Even today, when the pathophysiology of a disease is
not clearly related to a particular, usually structural, etiol-
ogy, it is common to attribute the disease to a psychogenic
cause, and this has its roots in the historical tension
between holism and dualism.
The concept of holism, from the Greek holos, or whole,
was first proposed by Plato, Aristotle, and Hippocrates in
ancient Greece.8 Holism postulates that the mind and body
are integrated and inseparable, and the study of medical
disease must take into account the whole person rather than
merely the diseased part. This approach accepts medical
symptoms and behavioral disturbances as legitimate fea-
tures of the individual and traditionally has existed in
Eastern cultures.
However, by the 17th century in Western Europe,
the concept of holism was eclipsed by the influence of thephilosopher René Descartes, who in 1637 proposed the
separation of the thinking mind (res cogitans) from
the machine-like body (res extensa).2 Descartes’s concept of
mind–body separation rapidly took hold on the backdrop of
evolving sociocultural influences, at the time relating to the
separation of church and state. Mind–body dualism had
profound effects on how medical disease became concep-
tualized. Until that time, the body could not be dissected
because the spirit was thought to reside there. Medical
investigation based on the writings of Galen related to
observation of the body and its humors. When the mind–
body dualism construct lifted the mind and soul from the
realm of the body, human dissection then would be
permitted, and this led to emerging knowledge of disease
pathology. Over the next few centuries, the morphologic
study of disease through pathology, then histopathology,
radiology, and nuclear imaging, led to many new diagnoses
and treatments for diseases.
However, with a morphologic construct, there was no
understanding of symptoms or behaviors in the absence of
pathology. In the 17th century, patients showing these fea-
tures were believed to be under demonic possession and, in
later centuries, were considered insane. They were rele-
gated to asylums and were excluded from scientific study.
Consequently, another result of Cartesian mind–body
dualism is that the study of behavioral abnormalities and
mental illness was marginalized; the mind as the seat of the
soul was not to be tampered with. Thus, it evolved in
Western society that behavioral abnormalities were not
available for study, and, in addition, mental illness or
physical symptoms in the absence of pathology were
considered second class: less legitimate than structural
disease and even stigmatized.9
In the United States, Benjamin Rush, a prominent
physician in the 18th century, sought to integrate psycho-
logical and medical knowledge in the diagnosis and treat-
ment of medical illness. However, after his death in 1813,
psychiatry was separated from medical practice and mental
illness remained unstudied in the asylums. Later in the
1800s, Louis Pasteur’s discovery of microorganisms and
Robert Koch’s development of the germ theory of disease
further moved medicine in the direction of biologic reduc-
tionism, in which diagnosis was related to specific etiologic
agents. However, in recent years (eg, with tuberculosis and
acquired immune deficiency syndrome) we now know that
infectious agents are conditional factors in disease etiology;
host resistance and the social environment also contribute
to the clinical expression of the disease.
Because of limited technology, explanatory models of
illness and disease through the 19th century developed from
natural observations, which then were interpreted in terms of
etiology. However, an important advance occurred in 1833
with William Beaumont’s studies of Alexis St. Martin, a voya-
geur who developed a traumatic gastric fistula from a gunshot
injury, thus allowing direct observation of gastric mucosal
color and secretion. Beaumont’s studies systematically re-
ported the association of emotions such as anger and fear with
gastric mucosal morphology and function, and was an early
psychophysiological investigation of the human GI tract.
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Gut and Brain Behavior (1900–1959)
Beaumont set the stage for further investigations of the
effects of emotion on gastrointestinal function. William
Cannon noted a cessation in bowel activity among cats
reacting to a growling dog. Ivan Pavlov studied surgically
produced fistulas in dogs, which led to an understanding of
the role of the vagus nerve in mediating the cephalic phase
of acid secretion. Later, studies of Tom and Monica, 2 people
with gastric fistulas studied by Steward Wolf and George
Engel, respectively, showed that different emotional con-
figurations are associated with distinct changes in gastric
function.2 Gastric hyperemia and increased motility and
secretion occurred with feelings of anger, intense pleasure,
or aggressive behavior patterns related to the subject’s
active engagement with the environment. Conversely,
mucosal pallor and decreased secretion and motor activity
occurred with fear or depression: states of withdrawal
(giving-up behavior) or disengagement from others. A series
of experiments by Tom Almy indicated that physical and
psychological stimuli led to increased sigmoid motility and
vascular engorgement in healthy subjects and in subjects
with irritable colon (irritable bowel syndrome [IBS]).2
Almy’s later studies with healthy subjects and IBS patients
using an emotive (stress) interview attempted to correlate
mood with motility. In healthy medical students, he noted
increased rectal contractility when falsely diagnosed with
cancer. He also reported increased motility concurrent with
states of aggression (particularly in those individuals with
constipation) and decreased motility associated with feel-
ings of helplessness (and diarrhea). Another important
observation during this period was by Alvarez,10 who
observed “nongaseous abdominal bloating” in women. He
noted that “the pronounced bloating is due not to any excess
gas in the digestive tract, but apparently to a contraction of
the muscles lining the back and the upper end of the
abdominal cavity..In addition there may be a relaxation of
the muscles of the anterior abdominal wall.”10 He also re-
ported that the swelling often occurred after a meal. These
findings preceded by decades the recent work using more
sophisticated assessment methods.11
These data provided scientific evidence that the gut is
physiologically responsive to emotion and environmental
(stressful) stimuli. However, the studies were limited
because the measurement techniques were rudimentary,
and unidirectional, and did not evaluate the reciprocal ef-
fects of changes in gut physiology on mental functioning.
Finally, the relation of these observations to actual gastro-
intestinal symptoms were rudimentary at best.
The Biomedical Era: Looking for Disease
Specificity: 1960–1979
With the impressive growth of medical technology after
1960, social and political forces moved scientists into an era
of biomedical research. The search for the etiology and
pathophysiology of disease took precedence over direct
observations of the patient. Psychosocial processes were
considered important but only as secondary phenomena,because “if the cause of a disease could be found and
treated, then certainly any psychosocial difficulties would
disappear.”9
Physiological investigation of the GI tract. More
scientific investigation of gut functioning began in the 1960s
with studies of secretory activity using gastrointestinal
tubes. By the early 1970s, technological improvements led
to new modalities to assess electromechanical function. GI
physiologists were developing and testing systems to assess
motor and electrical activity of the gut in most areas of the
GI tract and were able to delineate mechanisms for many of
the esophageal motor disorders (eg, achalasia, scleroderma)
and to determine the somewhat paradoxic mechanisms of
constipation (increased sigmoid pressures) and diarrhea
(decreased pressures).
A logical extension of this research effort was to explore
the pathophysiology of the functional GI disorders. These
disorders, represented primarily by IBS having both pain and
altered gut function, heretofore were unexplained, but the
symptomswere presumed to arise from intestinal dysmotility.
The studies showed that patients with IBS, when compared
with normal subjects, had an enhanced motor response to
various environmental stimuli such as psychological stress,
peptide hormone sand fatty meals, and increasedmotility was
associated, to a degree, with symptoms of pain.
Later in the 1970s, some investigators sought to find
biomarkers and one group reported a unique myoelectric
pattern, a basic electrical rhythm of 3 cycles/min in patients
with IBS, occurring at a frequency up to 40% of the time
that was thought to be specific for IBS. However, later work
did not reproduce these findings. Investigators also noted
that the correlation between altered motility and painful
symptoms was poor: experimentally induced motility in IBS
did not usually produce pain, and many patients with IBS
did not have abnormal motility when having pain.
Psychosocial and behavioral investigation of
functional GI disorders. For the most part, psychosocial
investigation during this period remained out of the main-
stream of biomedical research, and was limited to mental
health scientists and a few medical investigators whose
research was undertaken separately from physiological in-
vestigations. Psychological reports showed that patients
with IBS had a very high frequency of psychological distress
or disturbance. Some investigators then argued that IBS was
a psychiatric disorder akin to somatization. The ongoing
argument as to whether IBS was medical or psychiatric later
was clarified by epidemiologic and biopsychosocial studies
in the 1980s that evaluated gastrointestinal function and
symptoms along with psychological state simultaneously. It
was found that psychosocial distress enabled symptom
severity and illness behaviors, which led to health care
seeking. Thus, the prevalence of psychological disturbance
was greater in IBS patients rather than in those surveyed
who have IBS but are not patients.12,13
Given the variety of these somewhat dissimilar obser-
vations, it was difficult at the time to identify a unifying
concept for IBS. In subsequent years, Christensen14 even
questioned the existence of IBS as a distinct entity. Never-
theless his belief that “heterogeneity of pathological










EWprocesses must exist in such a diagnostic category”15
opened the door to research that later identified meaning-
ful biological subsets of IBS or, alternatively, disorders
considered distinctly separate from IBS. It also led in-
vestigators to consider alternative conceptualizations for
the symptoms of IBS relating to a more integrative multi-
component model as discussed later.Introduction of the Biopsychosocial Model and
Neurogastroenterology: 1980 to the Present
The 1980s began a period of major changes in the psy-
chosocial understanding of GI disease and illness. In the
1960s and 1970s, it was believed that technologic advances
would lead to finding a biological cause (and cure) of FGIDs.
However, by the end of this period, clinicians and scientists
were confronted with the inefficiencies of this model: (1)
diagnostic imaging and physiologic assessment did not fully
explain the symptoms of many patients presenting with
functional complaints, and, conversely, active disease was
not necessarily associated with symptoms; (2) the promi-
nence of psychosocial disturbances and illness behaviors
with chronic illness, particularly among those seen at
referral centers, was not seen among patients with the same
diagnoses in the community, and did not correlate well with
the observed physiological disturbance or disease pathol-
ogy; (3) social and political forces along with newer psy-
chosocial assessment methods such as health-related
quality of life led to interests away from disease and toward
the patients’ illness experiences; and (4) advances in
brain–gut physiology yielded findings that could not fit with
a dualistic biomedical concept.
Biopsychosocial (systems) model. The pivotal event
that brought together a unified understanding of health and
disease began in 1977 with the publications by George
Engel.1,16 These articles influenced many investigators andFigure 1. A biopsycho-
social conceptualization of
the pathogenesis, clinical
experience, and effects of
functional GI disorders.
There is a relationship be-
tween early life factors that
can influence the psycho-
social milieu of the individ-
ual, their physiological
functioning, as well as their
mutual interaction (brain–
gut axis). These factors
influence the clinical pre-
sentation of the disorder
and the clinical outcome.
Modified from Rome III.42clinicians away from seeking specific underlying biological
etiologies to a more integrated, biopsychosocial model of
illness and disease.1,2,16 Engel, an internist and psychoana-
lyst, offered a modern exposition of holistic (now called
systems) theory by proposing that illness is the product of
biological, psychological, and social subsystems interacting
at multiple levels; it is the combination of these interacting
subsystems that determines the illness (Figure 1).
The biopsychosocial or systems model offers certain
advantages: (1) an understanding of human illness that
reconciles the discrepancies between biomedical thought
and clinical observation; (2) a clinical framework for the
physician to integrate the broad range of biomedical and
psychosocial factors that explain the illness experience; and
(3) a unifying structure for multidisciplinary research
methodology and the inclusion of biopsychosocial assess-
ment in GI illness that emerged over the next few decades.
See the article “Biopsychosocial Aspects of FGIDs” for more
detail.
The research that evolved led to the following: (1) the
development of new questionnaires to assess broader psy-
chosocial domains such as health-related quality of life and
coping; (2) a shift in research articles focusing away from
solely physiological measurement to those that integrate
physiology with patient perceptions and behaviors; (3) in-
clusion of both psychosocial and physiological assessments
in treatment protocols; (4) evaluation of softer outcomes
(eg, health care use, daily function, symptom severity, gen-
eral well-being) than death or disease complications; and
(5) use of multivariate statistical methods to simultaneously
control for interacting biopsychosocial variables.
Neurogastroenterology. By the end of the 1990s,
newer clinical and translational techniques relating to gut
afferent signaling, neural stimulation and recording, pain
perception assessment, evaluation of the association be-
tween neural cells and immune functioning, and brain
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between the brain and gut, and this led to the concept of the
brain–gut axis. The term neurogastroenterology was
mentioned in Rome II in 1999 with the basic science and
physiology chapters17,18 as a means to reflect this emerging
field of research. In effect, neurogastroenterology reflects
the structural and physiological components of the bio-
psychosocial model, and the latter represents the clinical
research and application. The use of neurogastroenterology
as a research domain provides a level of legitimacy to
gut–brain research as never seen before.3 Over the past 2
decades, the term has been used by numerous research
societies, as well as journals and book publications.Gastrointestinal Symptoms, Syndromes,
and Diagnostic Criteria
The preceding history sets the stage for understanding
the place of functional gastrointestinal symptoms and syn-
dromes within gastroenterology, and it provides the basis
for the development of diagnostic criteria and the work of
the Rome Foundation.
Concepts of Gastrointestinal Disease, Motility, and
Functional GI Disorders. Table 1 identifies the major
clinical domains seen in gastroenterology.
1. The organic (structural) disorders (eg, esophagitis,
inflammatory bowel disease) are classified in terms of
organ morphology and the criterion for a disease is
pathology at a macro- or microlevel.
2. A motility disorder (eg, gastroparesis, intestinal
pseudo-obstruction), is classified in terms of organ
function and specifically altered motility. Although
dysmotility relates to abnormal visceral muscle ac-
tivity (ie, slow bowel transit, delayed gastric
emptying), a motility disorder is presumed to be
persistent or recurrent dysmotility recognized as a
clinical entity, and variably associated with symp-
toms. We also recognize that dysmotility may come
and go with repeated physiological testing.
3. A functional GI disorder (eg, IBS, functional dyspepsia)
relates to the patient’s interpretation and reporting ofTable 1.Major Clinical Domains in Gastroenterology
Organic
GI disorder
Primary domain Organ morphology O









IBD, inflammatory bowel disease.an illness experience, and it is classified primarily in
terms of symptoms. A symptom is a noticeable expe-
riential change in the body or its parts that is reported
by the patient as being different from normal and may
or may not be interpreted as meaningful. However, a
syndrome relates to the association of several clini-
cally recognizable symptoms or signs that occur
together to define a clinical entity. A functional GI
disorder is a syndrome based on symptoms that
cluster together and are diagnosed by Rome criteria.
Notably, there is overlap across these 3 domains. An
organic disorder such as ulcerative colitis, identified by gut
pathology, may be associated with a motility disturbance
and usually is associated with symptoms of pain and diar-
rhea, but neither the motility disturbance nor the symptoms
are necessary for the diagnosis. A motility disorder such as
gastroparesis is identified by a persistent motility distur-
bance (eg, delayed gastric emptying). It may occur from
altered gut neuronal morphology and often has symptoms
of nausea and vomiting, but patients do not necessarily have
symptoms that correlate with the disturbed motility.19
However, it is the motility finding that characterizes the
disorder. Similarly, a functional GI disorder such as IBS or
functional dyspepsia may have pathologic findings of in-
flammatory cells in the lamina propria of the gut or eosin-
ophils in the duodenum, respectively, as well as disturbed
motility, but histopathology is not necessary for defining a
functional GI disorder. The caveat is that although FGID
criteria primarily are symptom-based, there are exceptions,
such as with the anorectal disorders, in which physiological
findings are part of the criteria. Furthermore, identification
of biological substrates may help in terms of subclassifi-
cation and treatment.History of Rome Criteria for Diagnosis of
FGIDs and of the Rome Foundation
Pre-Rome: working team publications leading to
classification of FGIDs. This history began in Rome 30
years agowhenAldo Torsoli, Professor of Gastroenterology at
the University of Rome, was engaged in developing Working
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EWin Rome in 1988). By using the Delphi approach, he selected
experts from around the world to work through consensus to
answer difficult clinical questions that could not be answered
through scientific evidence at the time, and present their re-
sults at this meeting.20,21 Torsoli collaborated with W. Grant
Thompson, MD, from Ottawa, a respected gastroenterologist
studying in the nascent field of FGIDs to form a working team
to develop consensus criteria for the diagnosis of IBS.
Thompson et al22 were some of the few experts working on
epidemiologic, clinical, and psychosocial investigation of IBS
at the time. They then published the first diagnostic criteria
for IBS based on consensus.22
This IBS working team was generative of the later Rome
process, by generating diagnostic criteria by consensus
among experts globally. However, IBS was not the only
FGID. By the 1980s publications on other nonstructural,
symptom-based disorders were being studied: noncardiac
functional chest pain23; nonulcer dyspepsia24; post-
cholecystectomy pain25; bowel disorders related to bloating,
diarrhea, and constipation; and anorectal disorders
including fecal incontinence, difficult defecation, and rectal
pain.26,27 However, there was no overarching operational
definition or classification for them.
In 1989, Torsoli and Corazziari, a collaborator from the
University of Rome GI group, approached me to continue the
working team process. I proposed that we develop a clas-
sification system for all the FGIDs and that we create diag-
nostic criteria for them. With the support of the journal
Gastroenterology International we began the process of
creating a classification system with diagnostic criteria for
all of the FGIDs.
The first committee consisted of experts in the various
anatomic regions under consideration. They established 5
anatomic regions (esophagus, gastroduodenal, bowel,
biliary, and anorectal), and within each region identified
several disorders and for each categorized their clinical
features, diagnosis (using symptom-based criteria), and
treatment. They worked by e-mail over 2 years and met
once in the Gastroenterology International office in Rome to
consolidate the work and subsequently published it.28
Rome I: 1994. Over the next few years a series of
publications relating to each anatomic domain was elabo-
rated upon and published in Gastroenterology International.
Each member of the original committee created his own
working team of experts and elaborated on the epidemi-
ology, pathophysiology, psychosocial features, diagnostic
criteria, and treatment aspects of the diagnoses.29–33 Also,
given the poor standardization of clinical trials in the
functional GI disorders,34 we also created a working team to
provide guidelines for proper trials.35 Finally, with new
criteria for 21 functional GI disorders, we created a ques-
tionnaire to use in epidemiologic surveys and clinical
studies. This questionnaire was applied in the US House-
holder study, the first national epidemiologic database on
the prevalence, demographic factors, and health care–
seeking features of people with FGIDs.36
In 1994, the articles were compiled into a book: “The
Functional Gastrointestinal Disorders: Diagnosis, Patho-
physiology, and Treatment”37 and in retrospect isconsidered Rome I. Although the book sales were quite
limited, with fewer than 1000 copies sold, the 5 editors and
the 32 other internationally recognized committee members
creating these chapters began publishing studies using these
criteria. From this initiative, the concept of the FGID clas-
sification system and diagnostic criteria began to grow in
use.
Rome II: 1999–2000. By the mid-1990s, 2 factors
helped to promote the FGID classification and use of diag-
nostic criteria: the US Food and Drug Administration rec-
ommended the IBS criteria be used to select patients for
pharmaceutical studies, and the pharmaceutical industry
took interest in supporting the efforts of the Rome Foun-
dation. The Rome Foundation was incorporated in 1996,
and with the support of 8 pharmaceutical sponsors an in-
dustry council was created as a forum for the exchange of
ideas between the Rome Foundation and the sponsors.
However, to avoid any perception of influence, this council
was separate from the work of the Rome Board of Directors
or committees. Then, by the late 1990s, as a result of the
increased growth of publications in FGIDs, the Foundation
recruited 52 authors representing 13 countries to update
the literature and produce the Rome II book by 2000.38 In
addition, to gain Medline access, the committees produced
condensed versions of the chapters that were published in a
special issue of Gut in 1999.39
Rome III: 2006. After publication of Rome II, the
number of studies published using the Rome criteria in
clinical trials grew 8-fold over the next 12–14 years. The
Industry Advisory Council also expanded to include 12
pharmaceutical companies and at various times represen-
tatives from the Food and Drug Administration, Japanese
Regulatory Authority, the European Medicines Agency, and
the International Foundation of Functional GI Disorders. By
2002, the process began to produce Rome III, with the
addition of several new chapters and the recruitment of 87
authors representing 18 countries. Rome III differed from
Rome I and Rome II by the use of more evidence-based
rather than consensus-based data because research
studies were being published using the Rome criteria, which
allowed for more precise patient selection and with data
more representative of these disorders. The book was
published in May 2006,40 just after the publication of a
special Rome III issue of Gastroenterology, which contained
condensed versions of the book chapters.41
Rome IV: 2016. After 2006, the Rome Foundation
became increasingly recognized as an authoritative body
developing diagnostic criteria for research and also for
providing education about the FGIDs to clinicians, trainees,
and investigators worldwide. However, to meet their goal to
advance the field of FGIDs, the Foundation had to address
the following limitations: (1) the term functional GI disor-
ders, although entrenched in the literature, was imprecise
and to some degree stigmatizing; (2) the diagnostic criteria
were cumbersome to use in clinical practice; (3) the criteria
did not specify the investigative pathway to use before
applying the criteria; (4) the criteria oversimplified the
full dimension of the patients’ illness experience and were
not precise enough to identify meaningful physiological
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treatment; and (5) the Foundation traditionally approached
knowledge acquisition from a Western base of knowledge,
and this was a limitation to other countries and cultures.
Thus, the Rome Foundation made efforts to address these
limitations with Rome IV, as discussed later and further
delineated in the articles that follow. Although perhaps not
all of these limitations are addressed fully, Rome IV pro-
vides a foundation for future changes that will be made in
our understanding of these disorders.Definition
The definition of FGIDs has varied based on societal
perspectives of illness and disease over time, on the scien-
tific evidence, and on the clinician’s training and personal
biases. Even today, FGIDs are considered by many as less
legitimate than pathologically based diagnoses, and patients
with FGIDs may be stigmatized for having symptoms that
they consider to be very real. This originated as discussed
earlier from the influence of dualistic principles that sepa-
rate organic disorders, which are attributed by some to be
legitimate, and functional disorders, which often are
considered psychiatric or undefined.9 However, over time
and with each book publication, the definition has changed
from the absence of organic disease to a stress-related or
psychiatric disorder to a motility disorder, and with Rome
III, to a disorder of GI functioning.42
However, there is still a need for a meaningful working
definition to approach these disorders scientifically and
without bias. To achieve that for Rome IV, the Foundation
again relied on the Delphi method20,21 to create a definition
for FGIDs that is positive (rather than by the exclusion of
other disease), reflective of current scientific knowledge,
and nonstigmatizing. The new definition created by the
Board of Directors was shared among the chairs and
co-chairs of the Rome IV committees to obtain feedback for
modification and, ultimately, approval. The agreed-upon
definition is as follows: functional GI disorders are disor-
ders of gut–brain interaction. It is a group of disorders
classified by GI symptoms related to any combination of the
following: motility disturbance, visceral hypersensitivity,
altered mucosal and immune function, altered gut micro-
biota, and altered central nervous system (CNS) processing.
This definition is most consistent with our evolving un-
derstanding of multiple pathophysiological processes that in
part or together determine the symptom features that
characterize the Rome classification of disorders. We believe
it to be readily understood and acceptable to clinicians,
academicians, regulatory agencies, and the pharmaceutical
industry, as well as to patients.
Although the FGIDs share these physiological features in
common, their relative contribution may differ by bodily
location, the duration of symptoms, and across individuals
or within the same individual over time. For example, fecal
incontinence is primarily a disorder of motor function, while
centrally mediated abdominal pain syndrome (formerly
functional abdominal pain syndrome) primarily is amplified
central perception of normal visceral input. However, IBSappears to be more complex and may result from a com-
bination of factors relating to motility, visceral hypersensi-
tivity, mucosal immune dysregulation, alterations of
bacterial flora, and CNS–enteric nervous system dysregula-
tion. In addition, an individual who develops postinfection
IBS may have more influence from mucosal immune
dysfunction with altered microflora than another individual
with the same diagnosis with a lifelong history of chronic
symptoms and psychiatric comorbidities relating to altered
CNS regulation of GI function. Thus, the classification system
is an important component for categorizing these disorders,
but effective management requires a biopsychosocial
approach that addresses the variability and complexity of
patients who have these disorders.Rome IV Classification and
Criteria for FGIDs
The Rome Foundation classification of FGIDs is based
primarily on symptoms rather than physiological criteria.28
This has been favored because of its utility in clinical care,
limited evidence that physiological disturbance (ie, motility)
fully explained patient symptoms, and the fact that symp-
toms are what bring patients to health care providers.
However, physiological criteria still are permitted, as for the
anorectal disorders, if they increase diagnostic precision. We
believe that in the future biomarkers will be included in the
criteria if they can enhance their positive predictive value.
The classification of the disorders into anatomic regions
(ie, esophageal, gastroduodenal, bowel, biliary, and ano-
rectal) presumes unifying features underlying diagnosis and
management that relate to these organ locations. Thus,
functional heartburn relates to the esophagus, fecal incon-
tinence to the anorectum, and sphincter of Oddi (SOD)
disorder to the biliary system. However, symptom localiza-
tion is not enough, particularly painful FGIDs (eg, irritable
bowel syndrome, functional dyspepsia, and centrally medi-
ated abdominal pain syndrome) are not as easy to localize
and are influenced more by overarching effects resulting
from CNS–enteric nervous system dysregulation of symp-
tom control pathways.
Table 2 lists the 33 adult and 20 pediatric FGIDs for
Rome IV. In this issue, the articles covering the respective
anatomic domains listed will discuss the pathophysiology,
diagnostic features (including Rome IV criteria), and treat-
ment aspects.The Rome Committee Process
In addition to this special issue of Gastroenterology,
there are other educational materials created to address
the limitations stated earlier and that are part of Rome IV:
(1) a 2-volume textbook that more comprehensively covers
the information provided in this issue; (2) a book on
diagnostic clinical algorithms based on common symptom
presentations; (3) the Multidimensional Clinical Profile, a
case-based method to teach patient care by integrating the
multiple (diagnosis, psychosocial, physiological, severity)
components contributing to the illness; (4) a book of the
Table 2.Functional Gastrointestinal Disorders: Disorders of Gut–Brain Interaction
A. Esophageal Disorders
A1. Functional chest pain A4. Globus
A2. Functional heartburn A5. Functional dysphagia
A3. Reflux hypersensitivity
B. Gastroduodenal Disorders
B1. Functional dyspepsia B3. Nausea and vomiting disorders
B1a. Postprandial distress syndrome (PDS) B3a. Chronic nausea vomiting syndrome (CNVS)
B1b. Epigastric pain syndrome (EPS) B3b. Cyclic vomiting syndrome (CVS)
B2. Belching disorders B3c. Cannabinoid hyperemesis syndrome (CHS)
B2a. Excessive supragastric belching B4. Rumination syndrome
B2b. Excessive gastric belching
C. Bowel Disorders
C1. Irritable bowel syndrome (IBS) C2. Functional constipation
IBS with predominant constipation (IBS-C) C3. Functional diarrhea
IBS with predominant diarrhea (IBS-D) C4. Functional abdominal bloating/distension
IBS with mixed bowel habits (IBS-M) C5. Unspecified functional bowel disorder
IBS unclassified (IBS-U) C6. Opioid-induced constipation
D. Centrally Mediated Disorders of Gastrointestinal Pain
D1. Centrally mediated abdominal pain syndrome (CAPS)
D2. Narcotic bowel syndrome (NBS)/
Opioid-induced GI hyperalgesia
E. Gallbladder and Sphincter of Oddi (SO) Disorders
E1. Biliary pain
E1a. Functional gallbladder disorder
E1b. Functional biliary SO disorder
E2. Functional pancreatic SO disorder
F. Anorectal Disorders
F1. Fecal incontinence F2c. Proctalgia fugax
F2. Functional anorectal pain F3. Functional defecation disorders
F2a. Levator ani syndrome F3a. Inadequate defecatory propulsion
F2b. Unspecified functional anorectal pain F3b. Dyssynergic defecation
G. Childhood Functional GI Disorders: Neonate/Toddler
G1. Infant regurgitation G5. Functional diarrhea
G2. Rumination syndrome G6. Infant dyschezia
G3. Cyclic vomiting syndrome (CVS) G7. Functional constipation
G4. Infant colic
H. Childhood Functional GI Disorders: Child/Adolescent
H1. Functional nausea and vomiting disorders H2a1. Postprandial distress syndrome
H1a. Cyclic vomiting syndrome (CVS) H2a2. Epigastric pain syndrome
H1b. Functional nausea and functional vomiting H2b. Irritable bowel syndrome (IBS)
H2c. Abdominal migraine
H1b1. Functional nausea H2d. Functional abdominal pain ‒ NOS
H1b2. Functional vomiting H3. Functional defecation disorders
H1c. Rumination syndrome H3a. Functional constipation
H1d. Aerophagia H3b. Nonretentive fecal incontinence
H2. Functional abdominal pain disorders
H2a. Functional dyspepsia
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diagnosis in adults and children for research and clinical
care; (5) a primary care book; (6) a pediatric book; (7)
more than 800 graphic images to be used as slides and in
the online book; and (8) translations of the criteria to be
used for a global epidemiology survey to understand cross-
cultural differences in symptom experience and
presentation.
To accomplish this, Rome IV used a rigorous process of
prospective and retrospective data gathering, data syn-
thesis, data presentation, group decision making, and
extensive peer-review as indicated by the following
process.
1. In 2008 the Rome Foundation Board of Directors
identified key areas to acquire preliminary knowledge
for the Rome IV chapter committees to use. Commit-
tees were created to evaluate, compile, and publish
reviews in these areas of interest: brain imaging,43
severity in IBS44 intestinal microbiota,45 food/diet
and FGIDs,46–51 cross-cultural research (2014),52,53
development of an Asian questionnaire to address
cross-cultural differences in symptom interpreta-
tion,54 and primary care.55
2. Between 2010 and 2012 the Rome IV Editorial
Board was created, and they identified the chairs
and co-chairs of the 18 committees who in turn
selected their committee members to produce the
Rome IV chapters
3. Support committees were created to provide ancil-
lary service to the chapter committees: (1) a Ques-
tionnaire Committee to develop and validate the
Rome IV diagnostic criteria and create research
questionnaires, (2) a Systematic Review Committee
to perform systematic reviews and meta-analyses
for the chapter committees, (3) a Multidimensional
Clinical Profile committee to develop a case-based
book designed to improve patient care by using a
multicomponent assessment to target better treat-
ments,56 and (4) a Primary Care Committee to assess
and publish perspectives of primary care physicians
relating to IBS and FGIDs, and to create a primary
care book on Rome IV.
4. During Digestive Diseases Week 2013, the chapter
committees participated in an orientation in which
the support committees presented their work and
the new chapter committees were tasked to develop
online and printed book manuscripts and a journal
article for Gastroenterology. They also were reques-
ted to develop graphs and images for the online
book version, a revision of the Rome III diagnostic
algorithms,57 and a revision with additional cases for
the Multidimensional Clinical Profile book.56
5. From 2013 through the end of 2015 the committee
members critically synthesized the literature and
created the requested documents through several
revisions.6. In December 2014 the chapter committees met in
Rome (Rome IV Conference 2014) to revise the
documents and establish a consensus on the diag-
nostic criteria and scientific content.
7. At the end of the Rome meeting, the editorial board
and the chairs and co-chairs held a full-day harmo-
nization meeting to summarize and present their
committees’ recommendations to the group. This led
to feedback and discussion relating to gaps or re-
dundancies in content that were reconciled by
consensus.
8. The documents then were sent to up to 5 outside
international experts for peer-review and the docu-
ments were modified further as needed.
9. By autumn 2015, the manuscripts for the 13th issue
of Gastroenterology were created and reviewed by
the editorial board of Rome IV.
10. Finally, the committee members signed off on all
documents before it was sent to the copy editor for a
final check on content and style before publication.
Limitations in Using Rome Criteria
for Diagnosis and Management in
Clinical Practice
The Rome symptom-based categoric criteria are of
particular value for clinical research and pharmaceutical
trials. They provide a clear strategy for selecting study
subjects, they are endorsed by regulatory agencies, and are
used by clinical investigators and industry for clinical trials
around the world. Nevertheless, there are limitations for use
in clinical practice. A categoric diagnosis may exclude
patients who do not fully meet these criteria but who could
be treated similarly. A patient with abdominal pain and
bowel dysfunction for fewer than 6 months or fewer than 1
episode a week, or who does not meet 2 of the 3 criteria
associating pain with bowel habit, or who has pain not
associated with altered bowel habit, would not be diagnosed
by criteria as having IBS, yet the clinician could still judge a
need for treatment. Furthermore, patients can have 2 or
more FGID diagnoses (eg, IBS and functional dyspepsia),
although for the purpose of clinical trials the Rome IV
criteria exclude this co-occurrence. Thus, for clinical prac-
tice, meeting criteria may not be necessary in the daily care
of patients but still can serve as a useful guide to help
characterize these disorders.
Also, a diagnosis per se does not capture all dimensions
of the patient’s clinical condition to optimize treatment. For
example, a patient meeting criteria for functional dyspepsia
may have only occasional symptoms with no lifestyle
impairment and not require treatment. In contrast, another
patient with the same diagnosis with severe and disabling
pain, major depression, and weight loss from eating re-
strictions needs to be managed quite differently. In addition,
the criteria for cyclic vomiting syndrome does not require
the presence of pain, yet patients who meet criteria for this
diagnosis but who also have pain are more disabled, with










EWmore health care visits, and a greater likelihood of being
prescribed opioids leading to other complications. To
address these limitations in classification, the Multidimen-
sional Clinical Profile method teaches individualized treat-
ment based on identifying and integrating the multiple
components (psychosocial, clinical, physiological, quality of
life, and impact aspects) of the symptom experience.56Changes for Rome IV
Rome IV changes are as follows.
1. The addition of new diagnoses with known etiol-
ogies. Narcotic bowel syndrome (opioid-induced
gastrointestinal hyperalgesia) has been added to the
Centrally Mediated Disorders of Gastrointestinal
Pain article, opioid-induced constipation has been
added to the Bowel article, and cannabinoid hyper-
emesis syndrome has been added to the Gastrodu-
odenal article. These diagnoses differ from other
FGIDs by having substances (opioids and cannabi-
noids) that produce the symptoms, and their
avoidance may lead to recovery. Because these di-
agnoses result from known etiologies, they are not
truly functional, but we include them in Rome IV
because they fit the new definition: disorders of
gut–brain interaction being characterized by altered
function of the CNS or enteric nervous system; their
clinical presentations are similar to FGIDs and thus
need to be distinguished from them; and they have
not yet been well characterized or reached a level of
acceptance in the field to be considered separate
disorders (such as lactose intolerance, microscopic
colitis).
2. Removal of functional terminology when possible.
The debate to retain or change the term functional
has existed for decades, however, the word “func-
tional” has become so embedded in our health care
nosology that it cannot easily be substituted at this
time. However, the word “functional” has limitations
by being nonspecific and potentially stigmatizing.
Therefore, we provide an improved definition of
FGIDs (ie, disorders of gut–brain interaction) to help
clarify its meaning. In addition, we have removed the
word functional from article titles (eg, Esophageal
Disorders rather than Functional Esophageal Disor-
ders) and from certain diagnoses (eg, fecal inconti-
nence instead of functional fecal incontinence) as
occurred in Rome III. In addition, functional
abdominal pain syndrome has been changed to
centrally mediated abdominal pain syndrome to
more appropriately address the disorder’s patho-
genesis, minimize the stigma of the term functional,
and reverberate with the new brain–gut information
that is emerging. However, some clinical disorders
(eg, functional diarrhea, functional heartburn) have
retained the term to distinguish them from disor-
ders having similar symptoms but with clear struc-
tural etiologies.3. Article additions and modifications. A new article
entitled Intestinal Microenvironment and the Func-
tional Gastrointestinal Disorders combines knowl-
edge of the microbiome, food, and nutrition to
improve understanding of the luminal aspects of GI
function. Pharmacological and Pharmacokinetic As-
pects of Functional GI Disorders has been changed to
Pharmacological, Pharmacokinetic, and Pharmaco-
genomic Aspects of Functional Gastrointestinal Dis-
orders to include the role of genetics in the clinical
response to pharmaceutical treatments. Gender, Age,
Society, Culture and the Patient’s Perspective from
Rome III has been split into 2 articles to reflect the
rapid growth of knowledge in these areas of Age,
Gender, Women’s Health, and the Patient and
Multicultural Aspects of Functional Gastrointestinal
Disorders. Psychosocial Aspects of Functional
Gastrointestinal Disorders has been changed to
Biopsychosocial Aspects of Functional Gastrointes-
tinal Disorders to reflect the multidetermined nature
of biopsychosocial processes. The Rome III article
Functional Abdominal Pain Syndrome is changed to
Centrally Mediated Disorders of Gastrointestinal
Pain to reflect the predominant CNS contribution to
the symptoms.
4. Threshold changes for diagnostic criteria. With
limited information on normal bowel symptom
frequencies and inadequate data from the literature
on the frequency of GI symptoms using Rome
criteria, the Foundation conducted a Normative
Symptom Study so the chapter committees can
include evidence-based thresholds for judging
symptoms as out of the range of normal. The Rome
Foundation Questionnaire Committee conducted a
survey of physical symptoms including FGID
symptoms on a nonclinical nationwide sample in
the United States. Using this information, frequency
thresholds were created for the diagnostic criteria
that were different from general sample
frequencies.
5. Addition of reflux hypersensitivity diagnosis. In
Rome III, Functional Heartburn defined heartburn
symptoms in the absence of evidence that the
heartburn is associated with gastroesophageal
reflux. However, there also are patients who have
normal acid reflux levels, but they are sensitive to
the physiological reflux and so develop heartburn.
For Rome IV, A3 Reflux Hypersensitivity character-
izes this situation and is to be differentiated from A2
Functional Heartburn or even nonerosive reflux
disease by their greater association of symptoms
with reflux, albeit physiological.
6. Revision of SOD disorder criteria. Recommenda-
tions58 to perform biliary sphincterotomy based on
clinical criteria (biliary dilatation and increased liver
chemistries or increased pancreatic enzyme levels)
for presumed sphincter of Oddi pain has not had
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benefits of symptomatic relief with the potential
risks of pancreatitis, bleeding, and perforation has
been challenging, and the Rome III criteria for these
disorders were not particularly helpful in providing
proper guidelines. Now, driven by evidence that
debunks the value of sphincterotomy for type III
SOD,59 the Gallbladder and Sphincter of Oddi Dis-
orders chapter committee has reclassified these
disorders, and they provide a more rational algo-
rithm for treatment. The previous type III SOD
categorization of the Milwaukee classification has
been removed, so patients without evidence of bile
duct obstruction should not be referred for endo-
scopic retrograde cholangiopancreatography with
manometry for possible sphincterotomy. Instead,
they should be treated symptomatically. In addition,
treatment of functional biliary sphincter of Oddi
disorder in patients with only moderate objective
evidence of biliary obstruction should consider
other investigative options before a decision for
sphincterotomy is entertained.
7. Functional bowel disorders now exist on a spectrum
of symptom presentations. The predominant bowel
diagnoses of IBS with subtypes of constipation,
diarrhea, mixed, and unclassified, are no longer
considered distinct disorders. Instead, they exist on a
spectrum with linked pathophysiological features
that are variably expressed clinically by patient-
specific differences in the quantity, intensity, and
severity of symptoms. This overlap of clinical fea-
tures is well observed for IBS with predominant
constipation and chronic constipation in which cate-
gories may switch depending on the degree of pain
and across the subcategories of IBS related to
changes in stool habit over time.60–63 This also can
occur for IBS with functional dyspepsia or functional
constipation with pelvic floor dyssynergia. For clin-
ical trials, specific diagnostic criteria are necessary to
assess the targeted effects of the drugs, however, in
clinical care, patients may transition from one diag-
nosis to another or have combinations of diagnoses
that may require overarching management (eg, anti-
depressants for pain across multiple diagnoses).
8. Change in identification of IBS subtypes. The Rome
III classification for IBS subtypes required that the
proportion of total stools using the Bristol Stool
Form Scale be used to classify IBS with predominant
diarrhea (>25% loose/watery, <25% hard/lumpy),
IBS with predominant constipation (>25% hard/
lumpy, <25% loose/watery), mixed-type IBS
(>25% loose/watery, >25% hard/lumpy), and IBS
unclassified (<25% loose/watery, <25% hard/
lumpy). However, because patients can have large
periods of time with normal stool consistency, there
is a large number of patients with unclassified IBS
subtype relative to the other groups.64,65 Based onthis observation and the results of a Rome Founda-
tion Normative Symptom Study, the criteria for
subtypes of IBS have been changed and relate to the
proportion of symptomatic stools (ie, loose/watery
and hard/lumpy) rather than all stools (including
normal ones). As a result, the unclassified group is
reduced markedly.
9. Removal of the term discomfort from IBS criteria.
The Rome III criteria for IBS required abdominal
pain or discomfort, presuming that these terms exist
on a continuum from more severe (pain) to less
severe (discomfort). However, more recent data66
have indicated that patients consider the two
terms as qualitatively different, and discomfort can
incorporate a variety of symptoms. In addition, the
term discomfort has different meanings and is re-
ported with different frequencies across cultures.67
Therefore, to avoid symptom-related and cultural
heterogeneity, only the term pain is used as the key
diagnostic criterion for IBS.
10. Combined nausea and vomiting disorder. For Rome
IV the new diagnosis B3a. Chronic Nausea Vomiting
Syndrome combines the previous Rome III entities
Chronic Idiopathic Nausea and Functional Vomiting.
This is owing to a lack of evidence delineating
different diagnostic approaches and management of
nausea compared with vomiting, and the clinical
observation that these 2 symptoms commonly are
associated. Although we recognize that patients may
present only with nausea, the clinical approach to
diagnosis and management is still the same.Biopsychosocial Model of Functional
GI Disorders
Figure 1 shows an updated Biopsychosocial Conceptual
Model for functional gastrointestinal disorders68 (see the
article Biopsychosocial Aspects of Functional Gastrointes-
tinal Disorders). Early in life, genetics, sociocultural in-
fluences, and environmental factors may affect one’s
psychosocial development in terms of personality traits,
susceptibility to life stresses, psychological state, and
cognitive and coping skills. These factors also influence the
susceptibility to gut dysfunction: abnormal motility or
sensitivity, altered mucosal immune dysfunction or
inflammation, and the microbial environment, as well as
the effect of food and nutritional substances. Furthermore,
these brain–gut variables reciprocally influence CNS
expression.
An FGID is the product of these interactions of psycho-
social factors and altered gut physiology via the brain–gut
axis.68,69 Thus, an individual with bacterial gastroenteritis
who has a reduced inoculation of bacteria, no concurrent
psychosocial difficulties, and good coping skills may not
develop a clinical syndrome and, if it does develop, may
have mild symptoms and not perceive the need to seek
medical care. Another individual with a larger inoculation of










EWbacteria or a longer period of gastroenteritis, co-existent
psychosocial comorbidities, high life stress, abuse history,
or maladaptive coping may develop a severe syndrome of
postinfection IBS or dyspepsia, go to the physician
frequently, and have a generally poorer outcome.70–73
Furthermore, the clinical outcome will, in turn, affect the
severity of the disorder (Figure 1, double-sided arrow). For
example, a family that addresses the illness behavior
adaptively and attends to the individual and his or her
psychosocial concerns may reduce the impact of the illness
experience and resultant behaviors. Conversely, a family
that is overly solicitous to the person’s illness74 or a societal
group that interprets certain symptoms with threat may
amplify the symptoms and illness behaviors. With regard to
management, when the physician acknowledges the reality
of the patient’s complaints, provides empathy, and engages
in an effective physician–patient interaction, symptom
severity and health care seeking are reduced.75 In contrast,
the physician who does not engage in these skills and who
repeatedly performs unnecessary diagnostic studies to rule
out pathologic disease, dismisses the patient’s concerns, or
does not collaborate effectively in the patient’s care, is likely
to promote a vicious cycle of symptom anxiety and health
care seeking.76
Biopsychosocial Overview of Functional
GI Disorders
Using Figure 1 as a template, the concepts and associa-
tions of this model are discussed briefly and covered in
more detail in the article Biopsychosocial Aspects of Func-
tional Gastrointestinal Disorders.
Early life. A person’s genetic composition and in-
teractions with the environment affect later susceptibility to
disease, their phenotypic expression, as well as patient at-
titudes and behaviors (including health care seeking)
relating to it. Family and twin studies have indicated a ge-
netic component to IBS and likely other FGIDs, with several
polymorphisms and candidate genes that can affect physi-
ological functioning including motor function, membrane
permeability, and visceral sensitivity.77 However, Mendelian
single-gene susceptibility is unlikely; rather, multiple genes
likely interact with environmental risk factors to produce
the clinical heterogeneity among individuals with FGIDs,78
and psychophysiological factors such as stress may affect
the epigenetic expression of these genes, leading to visceral
hypersensitivity and other functions associated with these
disorders.79
Sociocultural factors and family interactions shape later
reporting of symptoms, the development of FGIDs, and
health care seeking. The expression of pain varies across
cultures from denial to stoicism to dramatic expression.
Symptoms such as bloating are reported commonly in
China, however, there is no word for bloating in Latin cul-
tures. With regard to health care use, diarrhea is highly
prevalent in Mexico and may not be considered an illness
leading to health care visits,5 and, in general, rural Latin
Americans are more likely to go to a local health care pro-
vider, a curandero, for common illnesses, and reserve seeinga traditional medical provider for more serious or life-
threatening diseases.4
Environmental exposures such as childhood Salmonella
infection can be a risk factor for IBS in adulthood.70 Early
learning difficulties or emotionally challenging interactions
in childhood may predispose to FGIDs. For example, diffi-
culties surrounding bowel habit80 or early abuse81 may
result in encopresis and even painful dyssynergic defecation
later in life, which can be reconditioned through anorectal
biofeedback.82 Early family attention toward GI symptoms
and other illnesses can influence later symptom reporting,
health behaviors, and health care costs.74
Psychosocial factors. Although psychosocial factors
are not required for diagnosis, they influence physiological
functioning of the GI tract via the brain–gut axis (motility,
sensitivity, barrier function), are modulators of the patient’s
pain experience and symptom behavior, and, ultimately,
affect treatment selection and the clinical outcome (see
article Biopsychosocial Aspects of FGIDs). When evaluating
for psychosocial factors, the clinician should consider four
general observations:
1. Psychological stress or one’s emotional response to
stress exacerbates gastrointestinal symptoms and
may contribute to FGID development. This occurs
among healthy subjects and patients with structural
diagnoses, and is well demonstrated in patients who
develop functional gastrointestinal disorders, a com-
mon example being postinfection IBS or dyspepsia.71
We also see a high association of psychosocial
comorbidities, life stress, and abuse among patients
with FGIDs, which lead to poorer outcomes.
2. Psychosocial factors modify the experience of illness
and illness behaviors such as health care seeking.
Although patients with FGIDs show greater psycho-
logical disturbance than otherwise healthy subjects
and patients with medical disease, the data are drawn
from patients seen at referral centers. This explains
why psychosocial trauma (eg, sexual or physical
abuse history) is more common in referral centers
than in primary care, may decrease the pain threshold
and symptom reporting, and is associated with a
poorer clinical outcome.72 These factors can be
reduced or buffered by adaptive coping skills and
social support. Thus, it follows that the psychosocial
response of family, society, and culture also can have
a palliative effect on the illness experience.
3. A functional GI disorder may have psychosocial con-
sequences. Any chronic illness has psychosocial con-
sequences on one’s general well-being, daily function
status, and sense of control over the symptoms, as
well as implications of the illness in terms of future
functioning at work and at home. This is understood
in terms of one’s health-related quality of life.
4. Psychosocial effects of illness, namely emotional
distress and maladaptive cognitions, may feed back to
perpetuate and amplify symptoms. Patients with
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and helplessness (ie, catastrophize) and selectively
attend to and be hypervigilant to their symptoms,
leading to visceral anxiety, all of which decreases
sensation thresholds and produces feelings of poor
self-efficacy and self-esteem. In these cases, a behav-
ioral intervention is needed to help re-establish a
psychological substrate of improved health.
Physiology. A variety of physiological processes may
lead to GI symptoms and, when more prevalent, to func-
tional GI disorders.
Abnormal motility. Disturbed gastrointestinal motility
can generate symptoms of nausea, vomiting, diarrhea, acute
abdominal pain, incontinence, and others. Furthermore, in
healthy subjects, and more so in patients with FGIDs, strong
emotion or environmental stress via the brain–gut axis can
lead to dysmotility throughout the GI tract. FGIDs have an
even greater motility response to stressors when compared
with normal subjects.83 However, these motor responses
only partially are correlated with symptoms, and are not
sufficient to explain reports of chronic or recurrent
abdominal pain.
Visceral hypersensitivity. The poor association of pain
with GI motility with many functional GI disorders (eg,
functional chest pain, functional dyspepsia–epigastric pain
syndrome, IBS, and so forth) is explained by the concept of
visceral hypersensitivity.84 These patients have a lower
pain threshold with balloon distension of the bowel
(visceral hyperalgesia), or they have increased sensitivity
even to normal intestinal function (eg, allodynia). Visceral
hypersensitivity may be amplified in patients with FGIDs:
repetitive balloon inflations in the colon lead to a pro-
gressive although transient increase in pain intensity in
healthy subjects and for a longer period in patients with
FGIDs. Hypersensitivity and sensitization may be amplified
at all levels of the brain–gut axis such as by factors listed
later.
Immune dysregulation, inflammation, and barrier
dysfunction. The work on postinfection IBS and dyspepsia
have been associated with increased interest in mucosal
membrane permeability via alteration of tight junctions,85
the intestinal flora, and altered mucosal immune func-
tion.86 These associations increase the access of intra-
luminal antigens into the submucosa associated with
low-grade activation of mast cells and increased inflam-
matory cytokine release.87 These actions alter receptor
sensitivity at the gut mucosa and myenteric plexus, pro-
ducing visceral hypersensitivity. Factors contributing to
this occurrence include genetics, psychological stress via
mast cell activation, and altered receptor sensitivity at the
gut mucosa and myenteric plexus. This is enhanced by
alteration of the bacterial environment or outright
infection.
Microbiome. The microbiome represents the collection
of microorganisms, which is shaped by host factors such as
genetics and nutrients, but in turn is able to influence host
biology in health and disease. It has become a major area for
research in gut functioning in the FGIDs, and there is also
an emerging concept of the microbiome–gut–brain axis.69,88Differences among IBS patients in the bacterial composition
of the gut (eg, increased firmicutes and reduced bacter-
oidetes and bifidobacter), and also reduced fecal microbial
diversity relative to healthy individuals, have implied a
causative role in the onset and maintenance of IBS. This is
supported by the modest effect of probiotics and more
substantive benefit of periodic antibiotic treatment in
improving IBS symptoms.45 However, further research is
needed to fully understand the place of the bacterial flora in
the pathogenesis of FGIDs.
Food, diet, and intraluminal factors. A recent addition
to understanding FGIDs relates to food and diet46 and also
their relationship to intestinal microbiota.89 Certain specific
alterations in diet such as low fermentable oligo-, di-, and
monosaccharides and polyols, or gluten restriction in some
patients, may provide benefit as a result of reduced osmotic
effects or alterations in gut mucosa. However, no one diet is
of specific value and treatment must be individualized. In
addition, the diet provides substrates for microbial
fermentation, and because the composition of the intestinal
microbiota is altered in IBS, the link between food and diet,
microbiota composition, and fermentation products may
play an important role in IBS pathogenesis. This is note-
worthy because there has been a discrepancy between
patients’ and physicians’ attributions to the effect of food
on FGID symptoms, with patients believing the effect was
more relevant.90 Further study is needed to define the
subsets of patients who are more likely to respond to al-
terations in diet.
Another recent area of interest relates to the effect of
intraluminal factors in addition to maldigested nutrients on
gut function. This includes microflora alterations in short-
chain fatty acids; the products of enteroendocrine cells
including granins and their effect on nervous, endocrine,
and immune cells; and the proportion of secondary to
primary bile acids, possibly affecting gut-transit rates.83
For example, the prevalence and role of cholerheic enter-
opathy likely has been underestimated previously in con-
ditions such as diarrhea-predominant IBS, and when
recognized can lead to a more specific treatment using bile
acid binders.
Brain–gut axis. The brain-gut axis is the neuroana-
tomic substrate in which the psychosocial factors just
described influence the GI tract and vice versa. The hard-
wiring between the brain and gut is a complex integrated
circuitry that communicates information from emotional
and cognitive centers (subserving thoughts, feelings, mem-
ories, and pain regulation) of the brain via neurotransmit-
ters (software) to the peripheral functioning of the GI tract
and vice versa.91 Structurally, there are direct connections
between the CNS and myenteric plexus to the visceral
muscles and other end-organ structures that affect sensory,
motor, endocrine, autonomic, immune, and inflammatory
function.92 Thus, emotions such as fear, anger, anxiety,
painful stimuli, and physical stress can delay gastric
emptying and intestinal transit. They also can stimulate
colonic motor function, reflected by decreased colonic
transit time, increased contractile activity, the induction of
defecation, and symptoms of diarrhea. Also, psychological
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mucosal secretory and barrier functions, and this is asso-
ciated with transmigration of bacterial cell products leading
to GI pain and diarrhea, as with IBS. Conversely, enhanced
motility, visceral inflammation, and injury can amplify
ascending visceral pathways and affect brain areas, leading
to greater pain and contributing to altered mental func-
tioning including anxiety and depression. In effect, the
reciprocal relationships that we call the brain–gut axis is
the neuroanatomic and neurophysiologic substrate for the
clinical application of the systems or biopsychosocial
model.93
With regard to pain regulation, the relationships
between psychosocial distress and painful symptoms ap-
pears mediated through impairment in the ability of various
brain networks such as the cingulate cortex to process
bodily pain. In effect, the brain’s pain control system can act
as a filter to enhance or block pain by up-regulating or
down-regulating the incoming neural signals affecting
symptom perception through this gate control mechanism.
Down-regulation, which increases the pain threshold, seems
not to occur as well in patients with functional GI pain. The
anterior cingulate cortex, involved in the motivational and
affective components of the emotional arousal and salience
network, is dysfunctional with IBS and other functional
GI pain, fibromyalgia, and other functional somatic symp-
toms. When this system is influenced by psychosocial
distress, the gate is open and the pain threshold is
decreased. Conversely, improvement in pain control can be
enabled by cognitive or emotional factors such as focused
attention, hypnosis, psychological treatment, and certain
antidepressants. These effects may be more than physio-
logical based on growing evidence for their role in
enhancing neurogenesis as well, thus possibly contributing
to more lasting effects for these treatments.94 A more recent
understanding expands upon the complexity of multiple
brain network operating systems including emotional
arousal, salience and executive functions, sensorimotor and
autonomic functions related to FGIDs.93 In sum, the clinical
phenotype that we understand as FGIDs emerges from the
interactions of multiple systems in the periphery (micro-
biome, altered mucosal inflammation, visceral hypersensi-
tivity) and in the brain (brain network systems of emotional
arousal, sensorimotor function, central autonomic function)
interacting with each other in bidirectional ways that lead to
the FGID phenotype.93
FGID symptom experience severity and behav-
ior. The product of the interacting effects of the brain and
GI tract in any individual with an FGID relates to the clinical
expression of illness; namely, the symptom experience, its
severity, and subsequent illness-related behaviors. This in-
cludes the meaning of illness, the fears of continued symp-
toms, the perceived concerns relating to alterations in body
image, social acceptability (eg, feeling stigmatized), the de-
gree of functional impairment with its implications at work
and at home, the sense of helplessness to effect symptom
relief, and the difficulty of coping with disability must all be
dealt with by the patient. How well the patient adapts basedon personal and family resources, in addition to the quality
of the physician’s involvement, is crucial to the patient’s
psychological well-being and clinical course. Given the
proper biopsychosocial milieu, many patients can adapt to
their illness with some support from family, friends, and
health care providers. Other patients, possibly shaped by
genetics and early experiences, respond by feeling helpless
and unable to feel in control of their symptoms and the
effects on their life; they regress and become dependent.
Their continued symptoms, restricted activity, and health
care needs may tax family, friends, and their physician, all of
whom may feel helpless to provide enough emotional or
medical assistance. If the patient has a limited capacity to
cope psychologically with the illness, the disorder is
particularly incapacitating, or if the interpersonal family
relationships are dysfunctional, additional efforts by the
physician and ancillary personnel (eg, psychological coun-
selors, social workers, peer support groups) will be
required.
Outcome. The outcome of the biopsychosocial model
as discussed is what we see in the patient’s health and
personal care behaviors, and in the impact on family, the
physician, and society. Psychosocial factors are strong de-
terminants of medication use, health care visits, functional
ability, loss of work time, and health care costs. All of these
factors can be addressed and potentially modified by the
physician’s ability to listen, engage, and effect good
communication skills, as discussed later, regardless of the
diagnostic condition.75An Approach to the Care of Patients
With Functional GI Disorders
Twelve Steps to Enhance the
Therapeutic Relationship
An effective physician–patient relationship can improve
patient satisfaction, adherence to treatment, symptom
reduction, and other health outcomes. This section provides
general care guidelines that can help to optimize this rela-
tionship for patients with FGIDs.75
1. Improve patient satisfaction and engage with the
patient. Patient satisfaction relates to the patient’s
perception of the doctor’s humaneness, technical
competence, interest in psychosocial factors, and
provision of relevant medical information, and too
much focus on biomedical issues can have a negative
effect. Engagement relies on nonverbal communica-
tion: good eye contact, affirmative nods, gentle tone
of voice, close interpersonal distance, and creation of
a partner-like interaction.
2. Obtain the history through a nondirective, nonjudg-
mental, patient-centered interview. This involves
active listening and using questions based on the
patient’s thoughts, feelings, and experiences rather
than on using a personal or preset agenda of
questions.















Physiological factors Primarily bowel dysfunction Bowel dysfunction and CNS
pain dysregulation
Primarily CNS pain dysregulation
Psychosocial difficulties None or mild psychosocial
distress
Moderate psychosocial distress Severe–high psychosocial distress,
catastrophizing, abuse history
Sex Men ¼ women Women > men Women >>> men
Age Older > younger Older ¼ younger Younger > older
Abdominal pain Mild/intermittent Moderate, frequent Severe/very frequent or constant
Number of other symptoms Low (1–3) Medium (4–6) High (7)
Health-related quality of life Good Fair Poor
Health care use 0–1/y 2–4/y 5/y
Activity restriction Occasional (0–15 days) More often (15–50 days) Frequent/constant (>50 days)
Work disability <5% 6%–10% 11%
NOTE. Based on Drossman et al.44
FBDSI, Functional Bowel Disorder Severity Index; IBS-SSI, IBS Symptom Severity Index.
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GIOVERVIEW3. Determine the immediate reason for the patient’s
visit (eg, What led you to see me at this time?) and
evaluate the patient’s verbal and nonverbal
communication. Some possible reasons include the
following: (a) new or exacerbating factors (dietary
change, concurrent medical disorder, side effects of
new medication), (b) personal concern about a
serious disease (eg, recent family death), (c) per-
sonal or family stressors (eg, recent or anniversary
of death or other major loss, abuse event, or history),
(d) worsening or development of psychiatric co-
morbidity (depression, anxiety), (e) impairment in
daily function (recent inability to work or socialize),
or (f) a hidden agenda such as narcotic or laxative
abuse or pending litigation or disability claims.
4. Conduct a careful physical examination and cost-
efficient investigation. A well-conducted physical
examination has therapeutic value.95
5. Determine what the patient understands of the
illness and his or her concerns (eg, What do you
think is causing your symptoms? or What concerns
or worries do you have about your condition?).
6. Elicit the patient’s understanding of the symptoms
(illness schema) and provide a thorough explanation
of the disorder that takes into consideration the pa-
tient’s beliefs. For example: “I understand you believe
you have an infection that has been missed; as we
understand it, the infection is gone but your nerves
have been affected by the infection to make you feel
like it is still there, similar to a phantom limb.”
7. Identify and respond realistically to the patient’s
expectations for improvement (eg, How do you feel I
can be helpful to you?).
8. When possible, provide a link between stressors
and symptoms that are consistent with the patient’sbeliefs. Many patients are unable or unwilling to
associate stressors with illness but most patients
will understand the stress of the illness on their
emotional state: “I understand you do not see
stress as causing your pain, but you have
mentioned how severe and disabling your pain is.
How much do you think that is causing you
emotional distress?”
9. Set consistent limits (eg, I appreciate how bad the
pain must be, but narcotic medication is not indi-
cated because it can be harmful).
10. Involve the patient in the treatment (eg, Let me
suggest some treatments for you to consider).
11. Make recommendations consistent with patient in-
terests (eg, Antidepressants can be used for
depression, but they also are used to “turn down”
the pain, and pain benefit occurs in doses lower than
that used for depression).
12. Help establish an ongoing relationship with you or in
association with a primary care provider (eg,
Whatever the result of this treatment, I am prepared
to consider other options, and I will continue to
work with you through this).
Symptom Severity as a Guide to Treatment
Although illness severity exists on a continuum, there is
heuristic value in separating FGIDs into mild, moderate, and
severe categories in planning treatment. Table 3 applies
primarily to IBS patients, the group that has been most
studied. Although this information may not fully represent
non–health care seekers or patients with other FGIDs, it is
presented to help the clinician understand the variability in
symptom reports, illness behaviors, and treatment recom-
mendations all based on severity factors. In general, the
greater the severity the more intervening psychosocial and










EWother comorbidities will influence the clinical presentation
and will require different treatments.
Mild symptoms. Patients with mild or infrequent
symptoms comprise approximately 40% of patients, are
seen more in primary care than in gastroenterology prac-
tices, and do not have major impairment in function or
psychological distress. Symptoms often are based on
gastrointestinal dysfunction (ie, vomiting, diarrhea, con-
stipation), and pain is minimal or mild and without other
comorbid physical symptoms. Patients with mild symptoms
do not usually have dominant psychiatric diagnoses and
their quality of life is good, but they may report concerns
about the implications of their symptoms on their life. These
patients do not make frequent medical visits and usually
maintain normal activity levels without restriction. Here,
treatment is directed toward the following
1. Education. Indicate that FGIDs are very real disorders in
which the gastrointestinal system is overly responsive
to a variety of stimuli such as food, hormonal changes,
medication, and stress. Pain resulting from spasm or
stretching of the gut, from a sensitive gut, or from both
can be experienced anywhere in the abdomen and can
be associated with other effects on gastrointestinal
function leading to symptoms (eg, pain, nausea, vomit-
ing, diarrhea). Both physiological and psychological
factors interact to produce symptoms.
2. Reassurance. First elicit the patient’s concerns and
then respond to them. This is usually done after
appropriate evaluation.
3. Diet and medication. Offending dietary substances
(eg, lactose, fermentable oligo-, di-, and mono-
saccharides and polyols, caffeine, fatty foods, alcohol)
and medications that adversely cause symptoms
should be identified and reduced or eliminated.
Sometimes a food diary is helpful.
Moderate symptoms. A smaller proportion of
patients, approximately 30%–35%, seen in primary or sec-
ondary care report moderate symptoms and have inter-
mittent disruptions in activity, for example, missing social
functions, work, or school. They may identify a close rela-
tionship between symptoms and inciting events such as
dietary indiscretion, travel, or distressing experiences. They
may have more moderate abdominal pain and be more
psychologically distressed than patients with mild symp-
toms. There may be several other medical or psychological
comorbidities, and these patients may lose time from work
or need to curtail usual functioning. For this group, addi-
tional treatment options are recommended.
1. Symptom monitoring. Keeping a symptom diary for
1–2 weeks encourages the patient’s participation in
treatment and sense of control over the illness. It may
help to identify inciting factors such as dietary in-
discretions, lifestyle factors, or specific stressors not
considered previously.
2. Pharmacotherapy directed at specific symptoms.
Medication can be considered for symptom episodesthat are distressing or that impair daily function. The
choice of medication depends on the predominant
symptoms. In general, prescription medications
should be considered as ancillary to dietary or life-
style modifications for mild chronic symptoms and
used during periods of acute symptom exacerbation,
or they may be required on a regular basis for
symptoms of moderate or frequent severity.
3. Psychological treatments. Psychological treatments
may be considered for motivated patients with
moderate-to-severe GI symptoms and for patients with
pain. It is more helpful if the patient can associate
symptoms with stressors. These treatments, which
include cognitive-behavioral therapy, relaxation, hyp-
nosis, mindfulness, and combination treatments, help
to reduce anxiety levels, encourage health-promoting
behaviors, and provide the patient with greater re-
sponsibility and control in the treatment and in
potentially improving pain tolerance. See the article
Biopsychosocial Aspects of FGIDs, for more details.
Severe symptoms. Approximately 20%–25% of pa-
tients with FGIDs often seen in referral practices have se-
vere symptoms and a smaller proportion have very severe
and refractory symptoms. They often have a high frequency
of associated psychosocial difficulties including anxiety,
depression or somatization, personality disturbance, and
chronically impaired daily functioning, and approximately
10% or more will have work disability. There may be a
history of major loss or abuse, poor social networks or
coping skills, and catastrophizing behaviors. These patients
may see gastroenterology consultants frequently and may
hold unrealistic expectations to be cured. Perhaps from
earlier experiences in the health care system, they may feel
stigmatized with their condition and deny or not consider a
role for psychosocial factors in the illness. As a result, they
may be unwilling to engage in psychological or psycho-
pharmacologic treatment but more often will seek further
diagnostic studies to legitimize their complaints and choose
pharmacologic treatments directed at the gut. For this
group, the following treatment options are recommended.
1. The physician’s approach. In addition to the general
12-step approach previously described, the clinician
also should: (a) perform diagnostic and therapeutic
measures based on objective findings rather than in
response to patient demands; (b) set realistic treat-
ment goals, such as improved quality of life rather
than complete pain relief or cure; (c) shift the re-
sponsibility for treatment to the patient by giving
therapeutic options; and (d) change the focus of care
from treatment of disease to adjustment to and
management of chronic illness.
2. Antidepressant treatment. If pain is a dominant
feature, tricyclic antidepressants (eg, desipramine,
amitriptyline) or the serotonin-norepinephrine reup-
take inhibitors (eg, duloxetine, milnacipran) help
control pain via central analgesia as well as provide
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GIOVERVIEWrelief of associated depressive symptoms. The selec-
tive serotonin reuptake inhibitors (eg, citalopram,
fluoxetine, paroxetine) are less effective for pain but
can help reduce anxiety and associated depression.
Antidepressants should be considered for patients
with chronic pain and impaired daily functioning, co-
existent symptoms of major depression, symptom
anxiety, or panic attacks. Even without depressive
symptoms, these agents may help when the pain is
dominant and consuming. For more information, see
the articles entitled, “Biopsychosocial Aspects of
FGIDs” and “Centrally Mediated Disorders of GI Pain.”
3. Functional GI or pain treatment center referral. There are
several GI programs and possibly pain treatment centers
that provide a multidisciplinary approach to FGID man-
agement.Here, the teamapproach isdirected towardpain
management, improved coping skills, and overall reha-
bilitation of patients who have become disabled.Concluding Comments
In providing an overview of the functional GI disorders
and the Rome Foundation process, we set the stage for the
information to follow. A great deal has happened in the 10
years since the publication of Rome III. We believe that this
new information will help the reader gain a better under-
standing of these disorders and improve the diagnosis and
care of his or her patients. Rome IV is the culmination of a
6-year effort of 117 internationally recognized in-
vestigators and clinicians representing 23 countries along
with 10 administrative staff and consultants. As we look
back on the process, the information obtained is compre-
hensive, although there is still more to learn. When more
advances in our understanding and treatment of these
disorders occur in future years, we will revise the infor-
mation again as we advance to Rome V. The Rome process
is a dynamic one, and we look forward to future activities
designed to help improve the science of FGIDs and care of
the patients.
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